DexCom (NASDAQ:DXCM) Director Sells $53,933.62 in Stock

DexCom, Inc. (NASDAQ:DXCM) Director Kyle Malady sold 667 shares of the business’s stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $80.86, for a total transaction of $53,933.62. Following the completion of the sale, the director owned 22,667 shares in the company, valued at $1,832,853.62. This represents a 2.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

DexCom Price Performance

DexCom stock opened at $76.00 on Friday. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $93.25. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. The firm’s 50-day simple moving average is $81.01 and its 200 day simple moving average is $78.80. The firm has a market capitalization of $29.80 billion, a PE ratio of 52.78, a P/E/G ratio of 1.59 and a beta of 1.48.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.45 by $0.03. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business’s revenue for the quarter was up 15.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. On average, equities research analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on DXCM. Morgan Stanley upped their target price on shares of DexCom from $82.00 to $89.00 and gave the company an “equal weight” rating in a report on Tuesday, July 15th. UBS Group upped their target price on shares of DexCom from $105.00 to $106.00 and gave the company a “buy” rating in a report on Thursday, July 31st. The Goldman Sachs Group began coverage on shares of DexCom in a report on Friday, May 30th. They issued a “buy” rating and a $104.00 target price on the stock. Citigroup restated a “buy” rating and issued a $102.00 target price (up from $82.00) on shares of DexCom in a report on Thursday, May 22nd. Finally, Truist Financial began coverage on shares of DexCom in a report on Monday, June 16th. They issued a “buy” rating and a $102.00 target price on the stock. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $99.89.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Andra AP fonden purchased a new position in shares of DexCom during the 2nd quarter worth about $26,000. Twin Peaks Wealth Advisors LLC purchased a new position in shares of DexCom during the 2nd quarter worth about $26,000. Golden State Wealth Management LLC lifted its holdings in shares of DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock worth $27,000 after acquiring an additional 264 shares during the period. Zions Bancorporation National Association UT purchased a new position in shares of DexCom during the 1st quarter worth about $27,000. Finally, Heck Capital Advisors LLC purchased a new position in shares of DexCom during the 4th quarter worth about $38,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.